Drug Pipeline Update

→ New drug information

- **Syndros™ (dronabinol oral solution):** The Food and Drug Administration (FDA) approved Insys Therapeutics’ Syndros for the treatment of human immunodeficiency virus (HIV) wasting and chemotherapy-induced nausea and vomiting. Dronabinol capsules are available generically for these indications. Syndros is the first and only FDA-approved dronabinol solution for oral use.

- **Xiidra™ (lifitegrast ophthalmic solution):** The FDA approved Shire’s Xiidra for the treatment of signs and symptoms of dry eye disease. Xiidra will compete with Allergan’s Restasis®, an eye drop approved to increase tear production.

- **Belviq® XR (lorcaserin):** The FDA approved Arena’s Belviq XR, a once-daily formulation of Belviq for weight loss. Previously, Belviq was administered twice per day.

- **Relistor® (methylnaltrexone):** The FDA approved an oral formulation of Valeant’s Relistor for the treatment of opioid-induced constipation. Previously, Relistor was administered every other day via subcutaneous injection.

→ New generics

- **Fenoglide® (fenofibrate 40 mg and 120 mg):** Mylan has launched the first generic version of Valeant’s Fenoglide for the treatment of high cholesterol. According to IMS Health, Fenoglide had U.S. sales of approximately $28.6 million for the 12 months ending April 30, 2016.

- **Ziana® (clindamycin phosphate/tretinoin gel, 1.2–0.025%):** Actavis has launched the first generic version of Valeant’s Ziana gel for the treatment of acne.

- **Mirapex® ER 3.75 mg (pramipexole ER tab, 3.75 mg):** Par has launched the first generic version of Boehringer Ingelheim’s Mirapex ER 3.75 mg tablets for the treatment of Parkinson’s disease.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. All brand names are property of their respective owners.